CA2362055A1 - A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample - Google Patents
A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample Download PDFInfo
- Publication number
- CA2362055A1 CA2362055A1 CA002362055A CA2362055A CA2362055A1 CA 2362055 A1 CA2362055 A1 CA 2362055A1 CA 002362055 A CA002362055 A CA 002362055A CA 2362055 A CA2362055 A CA 2362055A CA 2362055 A1 CA2362055 A1 CA 2362055A1
- Authority
- CA
- Canada
- Prior art keywords
- time
- profile
- dependent measurement
- slope
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
- G01N33/49—Blood
- G01N33/4905—Determining clotting time of blood
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
A method is disclosed for predicting the presence of haemo-static dysfunction. At least one time-dependent measurement (101) on an unknown sample (103) is performed and a respective prop-erty of the sample (103) is measured over time so as to derive a time-dependent measurement profile. One or more predictor vari-ables (110), including initial slope, are defined which sufficiently define the data of the time-dependent measurement profile. A model (113) is then derived that represents the relationship between an ab-normality and a set of predictor variables (110). Subsequently, the model (113) is utilized to predict haemostatic dysfunction.
Claims (41)
1. A method for predicting the presence of haemostatic dysfunction in a patient from at least one time-dependent measurement profile, comprising:
a) performing at least one time-dependent measurement on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile;
b) defining one or more predictor variables which define, at least in part, the data of the time-dependent measurement profile, said one or more predictor variables including the slope of the time-dependent measurement profile prior to clot formation;
c) deriving a model that represents the relationship between the haemostatic dysfunction and the one or more predictor variables; and d) utilizing the model of step c) to predict the existence of haemostatic dysfunction in the patient.
a) performing at least one time-dependent measurement on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile;
b) defining one or more predictor variables which define, at least in part, the data of the time-dependent measurement profile, said one or more predictor variables including the slope of the time-dependent measurement profile prior to clot formation;
c) deriving a model that represents the relationship between the haemostatic dysfunction and the one or more predictor variables; and d) utilizing the model of step c) to predict the existence of haemostatic dysfunction in the patient.
2. A method according to claim 1, wherein said at least one time-dependent measurement profile is at least one optical profile.
3. A method according to claim 3, wherein said at least one optical profile is provided by an automated analyzer for thrombosis and hemostasis testing.
4. A method according to claim 2, wherein a plurality of optical measurements at one or more wavelengths are taken over time so as to derive said at least one optical profile, said optical measurements corresponding to changes in light transmission through the patient sample.
5. A method according to claim 2, wherein a plurality of optical measurements are taken over time so as to derive said at least one optical profile, and wherein said plurality of optical measurements are each normalized to a first optical measurement.
6. A method according to claim 3, wherein in step a) said at least one optical profile is provided automatically by said analyzer, whereby said unknown sample is automatically removed by an automated probe from a sample container to a test well, one or more reagents are automatically added to said test well so as to initiate said property changes within said sample, and the development of said property over time is automatically optically monitored so as to derive said optical data profile.
7. A method according to claim 6, wherein after step d), a predicted congenital or acquired imbalance or therapeutic condition is automatically stored in a memory of said automated analyzer and/or displayed on said automated analyzer.
8. A method according to claim 6, wherein in step d), one or more assays for confirming the existence of said congenital or acquired imbalance or therapeutic condition is automatically performed.
9. A method according to claim 8, wherein said one or more confirming assays are automatically ordered and performed on said analyzer, with results of said one or more assays being stored in a memory of said automated analyzer and/or displayed on said analyzer.
10. A method according to claim 1, further comprising:
before step a), providing a set of data from known samples, which data is used in step c) for deriving said model.
before step a), providing a set of data from known samples, which data is used in step c) for deriving said model.
11. A method according to claim 10, wherein said data from known samples is provided by performing a plurality of assays on said known samples.
12. A method according to claim 1, wherein in step a), a plurality of time-dependent measurement profiles are derived for use in step b).
13. A method according to claim 12, wherein said plurality of time dependent measurement profiles includes at least two profiles from assays initiated with PT reagents, APTT reagents, fibrinogen reagents and TT reagents.
14. A method according to claim 1, wherein said unknown sample is a sample from a medical patient, and wherein in step d), both said model and additional patient medical data are utilized for predicting the existence of said congenital or acquired imbalance or therapeutic condition.
15. A method according to claim 14, wherein said additional patient medical data includes one or more of Fibrinogen, D-dimer or platelet count information.
16. A method according to claim 1, wherein in step (d), the prediction of haemostatic dysfunction is performed a plurality of times so as to monitor disease progression or regression in the patient.
17. A method according to claim 1, wherein the prediction of haemostatic dysfunction is a prediction of Disseminated Intravascular Coagulation.
18. A method according to claim 17, wherein said prediction of Disseminated Intravascular Coagulation is correct in at least 750 of predicted cases.
19. A method according to claim 1, wherein said time-dependent measurement profile is an optical transmission through a sample during an APTT assay.
20. A method according to claim 1, wherein said time-dependent measurement profile is an optical transmission through a sample during a PT assay.
21. A method according to claim 1, wherein in step (b), the slope of the time-dependent measurement profile is taken from end of blank time up to immediately before the initiation of clot formation or a predetermined time period.
22. A method according to claim 1, wherein said time-dependent measurement profile is an optical transmission profile and said one or more parameters includes minimum transmittance and/or clot time.
23. A method according to claim 1, wherein said predicted haemostatic dysfunction is due to one or more conditions associated with disseminated intravascular coagulation, including trauma, malignancy, surgery, aortic aneurysm rupture, and systemic inflammatory response syndrome.
24. A method according to claim 1, wherein said prediction of the existence of haemostatic dysfunction includes flagging the existence or likelihood of the haemostatic dysfunction.
25. A method according to claim 1, wherein the only predictor variable is said slope of the time-dependent measurement profile prior to clot formation.
26. A method according to claim 1, wherein the predictor variable of slope of the time-dependent measurement profile prior to clot formation is a slope which is less than about -0.0003.
27. A method according to claim 26, wherein said slope less than -0.0003 corresponds to activation of coagulation prior to initiation of clot formation.
28. A method according to claim 1, wherein the predicted haemostatic dysfunction is due to one or more of infection, trauma, major surgery, malignancy, hepatic disease, pregnancy and/or child birth, hypoxia, acidosis, lithium overdose, and graft rejection.
29. A method according to claim 24, wherein method steps (a) to (d) are performed on an automated or semi-automated analyzer, and said flagging is an alert to an individual operating said analyzer or an individual reading or evaluating the results of a test run on said analyzer, that there is a possibility or probability of haemostatic dysfunction of a patient whose test sample has been run on the analyzer and flagged.
30. A method according to claim 29, wherein said alert is an alert on a paper printout or on a monitor.
31. A method according to claim 27, wherein a slope of less than -0.0003 causes flagging of the patient sample, and wherein an increase in steepness of the slope from test to test corresponds to disease progression.
32. A method according to claim 1, wherein said patient sample is whole blood or a portion thereof.
33. A method according to claim 32, wherein said patient sample is a plasma sample.
34. A method according to claim 1, where said prediction of the existence of haemostatic dysfunction in the patient has a specificity and sensitivity greater than other tests used in diagnosing haemostatic dysfunction.
35. A method according to claim 1, wherein said haemostatic dysfunction is disseminated intravascular coagulation, and wherein said prediction of disseminated intravascular coagulation in the patient has a specificity and sensitivity greater than other tests performed for diagnosing disseminated intravascular coagulation.
36. A method according to claim 35, wherein said other tests are one or more of platelet count, determination of D-dimer level, and determination of fibrinogen level.
37. A method according to claim 1, wherein said haemostatic dysfunction predicted is disseminated intravascular coagulation, and wherein said method further comprises running platelet count, D-dimer level and/or fibrinogen level assays.
38. A method according to claim 1, wherein said slope is determined from blank time to initiation of clot formation or from blank time to a predetermined time period less than the time of initiation of clot formation, whichever is less.
39. A method according to claim 1, wherein the predictor variable of slope of the time-dependent measurement profile prior to clot formation is a slope less than about -0.0005.
40. A method according to claim 1, wherein said one.
or more predictor variables are a plurality of predictor variable further comprising one or more of a minimum of the first derivative of the profile, a time index of the minimum of the first derivative, a minimum of the second derivative of the profile, a time index of the minimum of the second derivative, a time index of the maximum of the second derivative, an overall change in the coagulation parameter during the time-dependent measurement on the unknown sample, a clotting time, a slope of the profile prior to clot formation, and a slope of the profile after clot formation.
or more predictor variables are a plurality of predictor variable further comprising one or more of a minimum of the first derivative of the profile, a time index of the minimum of the first derivative, a minimum of the second derivative of the profile, a time index of the minimum of the second derivative, a time index of the maximum of the second derivative, an overall change in the coagulation parameter during the time-dependent measurement on the unknown sample, a clotting time, a slope of the profile prior to clot formation, and a slope of the profile after clot formation.
41. A method for predicting the presence of disseminated intravascular coagulation in a patient from a time-dependent measurement profile, comprising:
a) performing a time-dependent measurement on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile;
b) computing the slope of the time-dependent measurement profile up to the initiation of clot formation or up to a predetermined time period less than the time of the initiation of clot formation, whichever is less;
c) computing a threshold for the parameter in c) from known positive and known negative samples which sufficiently separates positive and negative samples; and d) utilizing the threshold in step c) to predict the existence of disseminated intravascular coagulation in the patient.
a) performing a time-dependent measurement on an unknown sample and measuring a respective property over time so as to derive a time-dependent measurement profile;
b) computing the slope of the time-dependent measurement profile up to the initiation of clot formation or up to a predetermined time period less than the time of the initiation of clot formation, whichever is less;
c) computing a threshold for the parameter in c) from known positive and known negative samples which sufficiently separates positive and negative samples; and d) utilizing the threshold in step c) to predict the existence of disseminated intravascular coagulation in the patient.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US24434099A | 1999-02-04 | 1999-02-04 | |
US09/244,340 | 1999-02-04 | ||
PCT/US2000/002987 WO2000046603A1 (en) | 1999-02-04 | 2000-02-04 | A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2362055A1 true CA2362055A1 (en) | 2000-08-10 |
CA2362055C CA2362055C (en) | 2010-07-20 |
Family
ID=22922329
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2362055A Expired - Fee Related CA2362055C (en) | 1999-02-04 | 2000-02-04 | A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
Country Status (9)
Country | Link |
---|---|
US (1) | US7211438B2 (en) |
EP (1) | EP1147423B1 (en) |
JP (1) | JP4486260B2 (en) |
AT (1) | ATE282208T1 (en) |
AU (1) | AU774889B2 (en) |
CA (1) | CA2362055C (en) |
DE (1) | DE60015726T2 (en) |
ES (1) | ES2231167T3 (en) |
WO (1) | WO2000046603A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7732213B2 (en) * | 1999-02-22 | 2010-06-08 | Coramed Healthcare, Inc. | Method of evaluating patient hemostasis |
US6743596B1 (en) * | 2000-10-27 | 2004-06-01 | Biomerieux, Inc. | Method of determining global coagulability hemostatic potential |
WO2003073099A1 (en) * | 2002-02-27 | 2003-09-04 | Biomerieux, Inc. | Method for diagnosing and monitoring hemostatic dysfunction, severe infection and systematic inflammatory response syndrome |
BR0316197A (en) | 2002-11-12 | 2005-09-27 | Becton Dickinson Co | Kit, biomarker profile and method of isolating a host response biomarker |
WO2004044555A2 (en) | 2002-11-12 | 2004-05-27 | Becton, Dickinson And Company | Diagnosis of sepsis or sirs using biomarker profiles |
WO2005038690A2 (en) * | 2003-10-21 | 2005-04-28 | Philips Intellectual Property & Standards Gmbh | Method of automatically displaying medical measurement data |
EP1869463A4 (en) | 2005-04-15 | 2010-05-05 | Becton Dickinson Co | Diagnosis of sepsis |
US7480593B2 (en) * | 2005-08-03 | 2009-01-20 | Suresh Gopalan | Methods and systems for high confidence utilization of datasets |
US8548935B2 (en) * | 2008-02-14 | 2013-10-01 | Orion Diagnostica Oy | Predicting a future property using reagents by measuring properties at points in time |
US8669113B2 (en) | 2008-04-03 | 2014-03-11 | Becton, Dickinson And Company | Advanced detection of sepsis |
WO2011159820A1 (en) * | 2010-06-15 | 2011-12-22 | Bayer Healthcare Llc | Device |
US9910052B2 (en) | 2012-05-07 | 2018-03-06 | Lsi Medience Corporation | Method of diagnosing and treating infectious disseminated intravascular coagulation |
US9597001B2 (en) * | 2012-08-22 | 2017-03-21 | Ben-Gurion University Of The Negev Research & Development Authority | Separating clinically relevant sources of electrical activity in ECG signals |
US10823743B1 (en) | 2013-10-28 | 2020-11-03 | Ifirst Medical Technologies, Inc. | Methods of measuring coagulation of a biological sample |
JP6430809B2 (en) * | 2014-12-19 | 2018-11-28 | 公立大学法人奈良県立医科大学 | Method, system and computer program for determining blood sample, and blood sample analyzer |
EP3519828A4 (en) | 2016-09-29 | 2020-06-03 | Animantis, LLC | Methods and apparatus for assessing immune system activity and therapeutic efficacy |
EP3404665B1 (en) * | 2017-05-15 | 2024-03-06 | Medial Research Ltd. | Systems and methods for aggregation of automatically generated laboratory test results |
GB202004047D0 (en) | 2020-03-20 | 2020-05-06 | Ainger Phill | Point of care sepsis assay device and method |
US20240027476A1 (en) * | 2020-09-08 | 2024-01-25 | Sekisui Medical Co., Ltd. | Blood coagulation reaction analysis method |
JP2022062969A (en) * | 2020-10-09 | 2022-04-21 | シスメックス株式会社 | Blood sample analysis method, analysis device, and analysis program |
WO2022092248A1 (en) * | 2020-10-29 | 2022-05-05 | 積水メディカル株式会社 | Method for detecting blood coagulation reaction |
EP4303586A1 (en) * | 2021-03-05 | 2024-01-10 | Sekisui Medical Co., Ltd. | Method for estimating factor of prolonged coagulation time |
Family Cites Families (107)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US177089A (en) * | 1876-05-09 | Improvement in bit-stocks | ||
US1691741A (en) * | 1928-11-13 | Carrying bag and handle therefor | ||
US590665A (en) * | 1897-09-28 | Machine | ||
US1076086A (en) * | 1910-10-21 | 1913-10-21 | Charles C Vosburgh | Window-furnishing. |
US2070327A (en) * | 1931-06-08 | 1937-02-09 | Wood Newspaper Mach Corp | Paper roll braking mechanism |
US2005014A (en) * | 1932-04-19 | 1935-06-18 | Warner Brothers Pictures Inc | Focusing device for a motion picture camera |
US2012877A (en) * | 1932-11-03 | 1935-08-27 | Iwasa Morizo | Hearing appliance |
US2061953A (en) * | 1936-02-12 | 1936-11-24 | Sampson Max | Toy aeroplane and control therefor |
US2364453A (en) * | 1939-09-13 | 1944-12-05 | Standard Oil Co | Processing hydrocarbon distillates |
US2635081A (en) * | 1950-12-13 | 1953-04-14 | Sun Oil Co | Molybdenum disulfide on a spent cracking catalyst |
US3307392A (en) * | 1964-05-04 | 1967-03-07 | Research Corp | Automatic prothrombin timer apparatus and method |
US3458287A (en) * | 1965-04-29 | 1969-07-29 | Medical Laboratory Automation | Method and means of determining endpoint times in blood clotting tests |
US3502878A (en) * | 1967-09-22 | 1970-03-24 | Us Health Education & Welfare | Automatic x-ray apparatus for limiting the field size of a projected x-ray beam in response to film size and to source-to-film distance |
US3658480A (en) * | 1970-04-13 | 1972-04-25 | Bio Data Corp | Coagulation timing apparatus, and method |
US4047890A (en) * | 1973-11-01 | 1977-09-13 | Bio/Data Corporation | Method and apparatus for determining deficiencies in enzymatic reactors particularly clotting factor levels in blood plasmas |
SU590665A1 (en) | 1976-02-11 | 1978-01-30 | Новосибирский государственный медицинский институт | Method of investigating |
US4040788A (en) * | 1976-04-05 | 1977-08-09 | Sanford L. Simons | Apparatus, instrumentation, and method for comparing samples |
DE2635081C3 (en) | 1976-08-04 | 1980-08-07 | Bio/Data Corp., Willow Grove, Pa. (V.St.A.) | Method and apparatus for determining blood plasma coagulation factor levels |
FR2364453A1 (en) | 1976-09-08 | 1978-04-07 | Lacombe Pierre | Measurement of blood plasma coagulation time - using optical density method, suitable for oxalated or citrated plasma |
US4199748A (en) * | 1976-11-01 | 1980-04-22 | Rush-Presbyterian-St. Luke's Medical Center | Automated method and apparatus for classification of cells with application to the diagnosis of anemia |
JPS5451893A (en) | 1977-09-30 | 1979-04-24 | Sankyo Co | Measuring of blood coagulating time |
JPS5822703B2 (en) * | 1978-08-30 | 1983-05-10 | 三共株式会社 | Blood coagulation measurement method |
US4254760A (en) * | 1978-09-22 | 1981-03-10 | Sirimarco Robert A | Ceramic heat absorption panel |
US4289498A (en) * | 1979-01-08 | 1981-09-15 | Ortho Diagnostics, Inc. | One-stage prothrombin assay and compositions useful therein |
US4766083A (en) * | 1982-04-04 | 1988-08-23 | Wako Pure Chemical Industries, Ltd. | Method for the photometric determination of biological agglutination |
SU1076086A1 (en) | 1982-12-28 | 1984-02-29 | Всесоюзный Научно-Исследовательский И Конструкторский Институт Медицинской Лабораторной Техники | Hemocoagulograph |
EP0115459A3 (en) | 1983-01-26 | 1986-11-20 | University Of Medicine And Dentistry Of New Jersey | Hematological prediction of sepsis and other disease states |
US4705756A (en) | 1983-01-26 | 1987-11-10 | University Of Medicine And Dentistry Of New Jersey | Method of determining the existence and/or the monitoring of a pathological condition in a mammal |
JPS59203959A (en) | 1983-05-04 | 1984-11-19 | Toa Medical Electronics Co Ltd | Measuring device for blood clotting time |
JPH0695095B2 (en) | 1983-11-25 | 1994-11-24 | 株式会社島津製作所 | Fully automatic blood analyzer |
DE3502878A1 (en) | 1985-01-29 | 1986-07-31 | Boehringer Mannheim Gmbh, 6800 Mannheim | METHOD FOR DETERMINING THE FIBRINOLYTIC STATE OF PLASMA |
JPS61272655A (en) | 1985-05-28 | 1986-12-02 | Iryo Kogaku Kenkyusho:Kk | Quantitative discrimination method for platelet agglutination power |
GB8516081D0 (en) * | 1985-06-25 | 1985-07-31 | Ciba Geigy Ag | Assay & purification of amyloid components |
US4902630A (en) * | 1985-07-22 | 1990-02-20 | Abbott Laboratories | Fluorescence polarization immunoassy and reagents for measurement of c-reactive protein |
US5593897A (en) * | 1988-04-04 | 1997-01-14 | Northwestern University | Binding of immune complexes by modified forms of C-reactive protein |
DE68925899T2 (en) | 1988-04-04 | 1996-10-02 | Lawrence A Potempa | BINDING IMMUNE COMPLEXES BY MODIFIED FORMS OF C-REACTIVE PROTEINS |
US4965725B1 (en) * | 1988-04-08 | 1996-05-07 | Neuromedical Systems Inc | Neural network based automated cytological specimen classification system and method |
US5156974A (en) * | 1988-05-27 | 1992-10-20 | Biodata Corporation | Method for determining the fibrinogen level of a blood sample |
US5003065A (en) * | 1988-06-14 | 1991-03-26 | Carey Merritt | Compounds and process for measuring c-reactive protein |
US5697369A (en) * | 1988-12-22 | 1997-12-16 | Biofield Corp. | Method and apparatus for disease, injury and bodily condition screening or sensing |
US5055412A (en) * | 1989-03-21 | 1991-10-08 | Proksch Gary J | Factor sensitive reagent for testing of blood coagulation containing ellagic acid and divalent metal ions and method of making the same |
US5500345A (en) * | 1989-04-25 | 1996-03-19 | Iatron Laboratories, Inc. | Hybridomas producing monoclonal antibodies specific for C-reactive protein and methods for detection of C-reactive protein |
WO1991000872A1 (en) | 1989-06-27 | 1991-01-24 | Rush-Presbyterian-St. Luke's Medical Centre | Monoclonal antibodies to c-reactive protein |
US5051357A (en) | 1989-07-14 | 1991-09-24 | Board Of Trustees Operating Michigan State University | Method and assay using inactivation of factors Va and VIIIa by activated Protein C to diagnose thrombic disease or assay for Protein C and kit therefor |
WO1991001383A1 (en) * | 1989-07-14 | 1991-02-07 | Michigan State University | Method for diagnosing blood clotting disorders |
DE69033033T2 (en) | 1989-07-20 | 1999-10-28 | Analytical Control Syst Inc | IMPROVED CONTROL PROCEDURE FOR STABLE BLOOD COAGULATION |
SU1691741A1 (en) | 1989-08-25 | 1991-11-15 | Донецкий государственный медицинский институт | Method for prognostication of hemorrhagic complications secondary to traumatosis |
US4998535A (en) * | 1989-09-05 | 1991-03-12 | Univ. of Washington New England Medical Center Hospitals, Inc. | Thrombolysis predictive instrument |
US5262303A (en) | 1989-10-13 | 1993-11-16 | Trustees Of Boston University | Ligand/anti-ligand assays for adherent proteins |
US5646046A (en) * | 1989-12-01 | 1997-07-08 | Akzo Nobel N.V. | Method and instrument for automatically performing analysis relating to thrombosis and hemostasis |
IE904244A1 (en) | 1989-12-01 | 1991-06-05 | Akzo Nv | Direct fibrinogen assay |
US5169786A (en) | 1989-12-19 | 1992-12-08 | Ortho Diagnostic Systems, Inc. | Method of determining levels of extrinsic and intrinsic clotting factors and protein c |
ATE140034T1 (en) | 1990-04-17 | 1996-07-15 | Analytical Control Syst Inc | COAGULATION ASSAY AND REAGENTS |
US5862304A (en) * | 1990-05-21 | 1999-01-19 | Board Of Regents, The University Of Texas System | Method for predicting the future occurrence of clinically occult or non-existent medical conditions |
US5218529A (en) * | 1990-07-30 | 1993-06-08 | University Of Georgia Research Foundation, Inc. | Neural network system and methods for analysis of organic materials and structures using spectral data |
JPH04254760A (en) | 1991-01-30 | 1992-09-10 | Eiken Chem Co Ltd | Serum amyloid a reference substance and setting method thereof |
US5221628A (en) * | 1991-03-19 | 1993-06-22 | Northwestern University | Binding of aggregated immunoglobulin or immune complexes by serum amyloid P component |
RU2012877C1 (en) | 1991-04-01 | 1994-05-15 | Белорусский научно-исследовательский институт охраны материнства и детства | Method of prognosticating pulmonary disorder syndrome in premature neonates |
US5180835A (en) * | 1991-06-25 | 1993-01-19 | American Cyanamid Company | Process for the preparation of monomeric tetramethoxymethylglycoloril |
ES2094212T3 (en) | 1991-08-02 | 1997-01-16 | Grifols Grupo Sa | PROCEDURE AND APPARATUS FOR THE DETERMINATION OF THE COAGULATION TIME OF BLOOD AND PLASMA. |
AU2870992A (en) | 1991-10-04 | 1993-05-03 | Board Of Regents Of The University Of Nebraska, The | A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins |
US5716795A (en) * | 1991-10-04 | 1998-02-10 | Matschiner; John T. | Thrombomodulin-based coagulometric assay of the protein C system |
CA2121680C (en) | 1991-11-04 | 2005-03-22 | Andrew E. Senyei | Screening method for identifying women at increased risk for preterm delivery |
JPH05180835A (en) | 1991-12-27 | 1993-07-23 | S R L:Kk | Measurement of loops anti-coagulant |
US5318958A (en) | 1992-05-29 | 1994-06-07 | Queen's University At Kingston | Amyloid precursor protein |
JP2934557B2 (en) | 1992-07-10 | 1999-08-16 | 国際試薬株式会社 | Blood coagulation time measuring method and apparatus |
JPH0636061A (en) * | 1992-07-21 | 1994-02-10 | Fujitsu Ltd | Learning system of hierarchic neural network |
US5388164A (en) * | 1992-08-19 | 1995-02-07 | Olympus Optical Co., Ltd. | Method for judging particle agglutination patterns using neural networks |
JP3224607B2 (en) | 1992-09-11 | 2001-11-05 | 株式会社アズウェル | Method for measuring blood coagulation factor XIII activity and reagent kit for the measurement |
US5369484A (en) | 1992-11-09 | 1994-11-29 | Akzo N.V. | Multiple discrete analyzer test apparatus and method |
US5358852A (en) * | 1992-12-21 | 1994-10-25 | Eastman Kodak Company | Use of calcium in immunoassay for measurement of C-reactive protein |
RU2070327C1 (en) | 1992-12-25 | 1996-12-10 | Безруков Александр Васильевич | Device for measurement of coagulation time |
US5344754A (en) | 1993-01-13 | 1994-09-06 | Avocet Medical, Inc. | Assay timed by electrical resistance change and test strip |
JP2938302B2 (en) | 1993-02-25 | 1999-08-23 | 国際試薬株式会社 | Blood coagulation time measuring method and apparatus |
JPH06249857A (en) * | 1993-02-26 | 1994-09-09 | Hitachi Ltd | Automatic analyzing device |
RU2061953C1 (en) | 1993-03-10 | 1996-06-10 | Тюменский государственный медицинский институт МЗ РФ | Method for qualitatively determining general coagulation activity of blood platelets |
US5670329A (en) * | 1993-05-28 | 1997-09-23 | Cardiovascular Diagnostics, Inc. | Method and analytical system for performing fibrinogen assays accurately, rapidly and simply using a rotating magnetic field |
EP0633473B1 (en) * | 1993-06-30 | 1999-03-10 | Stiftung Für Diagnostische Forschung | Measurement of the activated partial thromboplastin time (APTT) in a single-step reaction |
JP3476826B2 (en) | 1993-08-16 | 2003-12-10 | アクゾ・ノベル・エヌ・ベー | Method and apparatus for automatically performing an analysis involving thrombus and hemostasis |
US5526111A (en) * | 1993-08-31 | 1996-06-11 | Boehringer Mannheim Corporation | Method and apparatus for calculating a coagulation characteristic of a sample of blood a blood fraction or a control |
US5472852A (en) | 1993-09-15 | 1995-12-05 | Oklahoma Medical Research Foundation | Assay for detection of selective Protein C inhibition by patients |
US5473732A (en) * | 1993-11-02 | 1995-12-05 | Chang; Hou-Mei H. | Relational artificial intelligence system |
US5553616A (en) * | 1993-11-30 | 1996-09-10 | Florida Institute Of Technology | Determination of concentrations of biological substances using raman spectroscopy and artificial neural network discriminator |
US5856114A (en) * | 1994-03-21 | 1999-01-05 | The University Of Vermont | Immunologic detection of factor VA fragments in hemorrhagic and thrombotic clinical settings |
WO1995030154A1 (en) | 1994-04-28 | 1995-11-09 | Dade International Inc. | Calibrator for prothrombin time (pt) assays |
AU1287595A (en) | 1994-08-26 | 1996-03-22 | Immtech International, Inc. | A mutant protein and methods and materials for making and using it |
US5504011A (en) * | 1994-10-21 | 1996-04-02 | International Technidyne Corporation | Portable test apparatus and associated method of performing a blood coagulation test |
SE9403833D0 (en) * | 1994-11-08 | 1994-11-08 | Global Hemostasis Inst Mgr Ab | Analysis procedure and kit |
US5705395A (en) * | 1994-11-14 | 1998-01-06 | The Scripps Research Institute | Method for diagnosis of thrombotic disorders |
US5567596A (en) * | 1994-12-29 | 1996-10-22 | Research Foundation Of State University Of New York | Rapid assay of activators and inhibitors of clotting |
EP0802986B1 (en) | 1995-01-10 | 2001-09-19 | Hendrik Coenraad Hemker | Methods of determining endogenous thrombin potential (etp) and thrombin substrates for use in said methods |
US5708591A (en) * | 1995-02-14 | 1998-01-13 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions |
US6321164B1 (en) * | 1995-06-07 | 2001-11-20 | Akzo Nobel N.V. | Method and apparatus for predicting the presence of an abnormal level of one or more proteins in the clotting cascade |
US6898532B1 (en) * | 1995-06-07 | 2005-05-24 | Biomerieux, Inc. | Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample |
US6429017B1 (en) * | 1999-02-04 | 2002-08-06 | Biomerieux | Method for predicting the presence of haemostatic dysfunction in a patient sample |
US5780255A (en) | 1995-06-09 | 1998-07-14 | Instrumentation Laboratory, S.P.A. | Protein C pathway screening test |
US6194163B1 (en) | 1995-07-21 | 2001-02-27 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Method for the quantitative measurement of human acute phase serum amyloid A protein; recombinant protein; specific antibody |
US5766869A (en) | 1995-11-30 | 1998-06-16 | Ahs Hospital Corp. | Factor V ratio blood test for susceptibility to thromboembolism |
AU717559B2 (en) | 1996-03-22 | 2000-03-30 | Dade Behring Inc. | Combination reagent holding and test device |
JPH1026621A (en) | 1996-07-12 | 1998-01-27 | Dai Ichi Pure Chem Co Ltd | Immunoassay method |
JP3876022B2 (en) | 1996-09-26 | 2007-01-31 | 生化学工業株式会社 | Method for quantifying substances that affect blood clotting time |
EP0841566A1 (en) | 1996-11-11 | 1998-05-13 | Pentapharm A.G. | Positive control plasma for lupus anticoagulant |
DE69829293T2 (en) * | 1997-04-02 | 2006-04-13 | The Brigham And Women's Hospital Inc., Boston | USE OF A MEANS TO REDUCE THE RISK OF CARDIOVASCULAR DISEASES |
US6010911A (en) * | 1997-04-30 | 2000-01-04 | Medtronic, Inc. | Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique |
US6027115A (en) * | 1998-03-25 | 2000-02-22 | International Game Technology | Slot machine reels having luminescent display elements |
US6249855B1 (en) * | 1998-06-02 | 2001-06-19 | Compaq Computer Corporation | Arbiter system for central processing unit having dual dominoed encoders for four instruction issue per machine cycle |
AU8679298A (en) * | 1998-07-31 | 2000-02-21 | Wallace E. Carroll | Method and apparatus for determining anticoagulant therapy factors |
-
2000
- 2000-02-04 WO PCT/US2000/002987 patent/WO2000046603A1/en active IP Right Grant
- 2000-02-04 AT AT00913371T patent/ATE282208T1/en not_active IP Right Cessation
- 2000-02-04 EP EP00913371A patent/EP1147423B1/en not_active Expired - Lifetime
- 2000-02-04 AU AU34833/00A patent/AU774889B2/en not_active Ceased
- 2000-02-04 DE DE60015726T patent/DE60015726T2/en not_active Expired - Lifetime
- 2000-02-04 ES ES00913371T patent/ES2231167T3/en not_active Expired - Lifetime
- 2000-02-04 CA CA2362055A patent/CA2362055C/en not_active Expired - Fee Related
- 2000-02-04 JP JP2000597634A patent/JP4486260B2/en not_active Expired - Fee Related
-
2004
- 2004-07-02 US US10/884,293 patent/US7211438B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
EP1147423A4 (en) | 2002-04-17 |
US7211438B2 (en) | 2007-05-01 |
JP2002541431A (en) | 2002-12-03 |
AU3483300A (en) | 2000-08-25 |
DE60015726T2 (en) | 2005-12-22 |
EP1147423A1 (en) | 2001-10-24 |
ATE282208T1 (en) | 2004-11-15 |
ES2231167T3 (en) | 2005-05-16 |
EP1147423B1 (en) | 2004-11-10 |
US20040248308A1 (en) | 2004-12-09 |
JP4486260B2 (en) | 2010-06-23 |
WO2000046603A1 (en) | 2000-08-10 |
DE60015726D1 (en) | 2004-12-16 |
AU774889B2 (en) | 2004-07-08 |
CA2362055C (en) | 2010-07-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2362055A1 (en) | A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample | |
EP0834145B1 (en) | A method and apparatus for predicting the presence of congenital and acquired imbalances and therapeutic conditions | |
AU2008201621B8 (en) | A method for predicting the presence of haemostatic dysfunction in a patient sample | |
JP2002500360A (en) | Method for predicting abnormal levels of coagulation proteins | |
JP7220055B2 (en) | Method for evaluating blood coagulation function | |
AU6617900A (en) | A method for predicting the presence of haemostatic dysfunction in a patient sample | |
US6898532B1 (en) | Method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample | |
Wang et al. | Prediction of thrombophilia in patients with unexplained recurrent pregnancy loss using a statistical model | |
WO2003085400A1 (en) | Onset of force development as a marker of thrombin generation | |
Subramanian et al. | Evaluation of the utility of thromboelastography in a tertiary trauma care centre | |
CA2377528C (en) | Method and apparatus for presenting thrombosis and hemostasis assay data | |
de Laat-Kremers et al. | Deciphered coagulation profile to diagnose the antiphospholipid syndrome using artificial intelligence | |
WO2016097312A1 (en) | Method for determining the fibrinogen concentration in a biological sample | |
RU2735988C1 (en) | Method for assessment of dynamics and completeness of contraction of blood clots for prediction of probability of spontaneous abortion | |
KR20210044711A (en) | Apparatus and method for analyzing the resulting data of blood coagulation test | |
EP1522860A1 (en) | A method and apparatus for predicting the presence of haemostatic dysfunction in a patient sample | |
Kampelos et al. | Serial rotational thromboelastometry measurements show worsening hypocoagulability in acute-on-chronic liver failure and are associated with the severity of liver disease | |
Subramanian et al. | Research Article Evaluation of the Utility of Thromboelastography in a Tertiary Trauma Care Centre | |
Cantarovich et al. | The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end stage renal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20140204 |